Medical Science News

RSS

University of Nevada professor awarded NIH RO1 grant for study of control of motility in internal anal sphincter

Kathleen Keef, Ph.D., professor of physiology and cell biology at the University of Nevada School of Medicine, has been awarded a four-year, $1.2 million grant from the National Institute of Health to study the control of motility in the internal anal sphincter.

22 Apr 2010

Agios Pharmaceuticals presents data on cancer-associated IDH1 mutations at 101st AACR meeting

Agios Pharmaceuticals, a biopharmaceutical company focused on discovering and developing novel drugs in the field of cancer metabolism, today announced multiple presentations at the American Association for Cancer Research (AACR) 101st Annual Meeting that highlight cancer metabolism as an approach to identify new ways to treat cancer, opening the potential for a new class of cancer drugs targeting metabolic enzymes.

22 Apr 2010

SpectraCell Laboratories introduces apolipoprotein E genotyping

Effective immediately, SpectraCell Laboratories now offers apolipoprotein E genotyping. This test determines a person's genetic risk for heart disease associated with the commonly studied gene called apoE, which is involved in the metabolism of cholesterol and triglycerides (fats in the blood).

22 Apr 2010

Study links mutations in RAD51C gene to breast and ovarian cancer

The discovery 15 years ago that the genes BRCA1 and BRCA2 confer high risks for breast and ovarian cancer was a breakthrough for cancer prediction and therapy, especially for familial cases. Now the research group of Prof. Alfons Meindl (Klinikum rechts der Isar of the Technische Universitaet Muenchen), in collaboration with other groups from Germany, the U.K., and the U.S., can identify another gene that increases susceptibility to breast and ovarian cancer.

22 Apr 2010

No more needles for vaccines – a two minute Nanopatch may suffice, say researchers

Vaccines have been associated with painful injections for a very long time. In a new and important discovery researchers have developed special ‘nano patches’ that can deliver vaccines without needles in just two minutes using 100 times less dose than used conventionally.

22 Apr 2010

Affymetrix reports first-quarter total revenue of $80.2M

Affymetrix, Inc., today reported its operating results for the first quarter of 2010. Total revenue for the quarter was $80.2 million, as compared to total revenue of $78.6 million in the first quarter of 2009.

22 Apr 2010

Red wine consumption may protect brain from stroke damage, say Johns Hopkins researchers

Researchers at Johns Hopkins say they have discovered the way in which red wine consumption may protect the brain from damage following a stroke.

22 Apr 2010

Curis presents data on CU-906 compound designed to inhibit HDAC and PI3K/mTOR targets simultaneously

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that data provided in a presentation entitled, "Antitumor activity of single small molecule agent targeting PI3K/mTor and HDAC," were presented at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010, which is being held in Washington, DC April 17-21.

21 Apr 2010

BIO-key International, Healthcare-ID to present biometric identity solutions at 56th CBBS Annual Meeting

BIO-key International, Inc., a leader in finger-based biometric identification solutions, today announced that BIO-key and its partner, Healthcare-ID, a leader in automated donor management solutions, will jointly participate at the 56th Annual Meeting of the California Blood Bank Society in BOOTH #123.

21 Apr 2010

CDI's iCell Cardiomyocytes named to MIT Technology Review's Annual 10 Emerging Technologies List

Cellular Dynamics International (CDI) today announced that CDI's development and commercialization of human cardiomyocytes for drug discovery and toxicity testing, based on the work of CDI co-founder and chief scientific officer, James A. Thomson, Ph.D., on induced pluripotent stem cell (iPSCs) technology, have been named to the MIT Technology Review's Annual 10 Emerging Technologies List.

21 Apr 2010

NCGR deploys Isilon scale-out NAS to power genome sequencing research services

Isilon Systems today announced that the National Center for Genome Resources has deployed Isilon scale-out NAS to power its full range of next-generation genome sequencing research services. By combining Isilon's X-Series, Backup Accelerator and CommVault's Simpana backup software, NCGR has unified eight Illumina Genome Analyzers onto a highly reliable, central storage resource, accelerating time-to-results and ensuring its research information is secure and accessible 24x7x365.

21 Apr 2010

Study helps understand molecular mechanism underlying taurine's protection against hepatic fibrosis

Hepatic fibrosis (HF) occurs in most types of chronic liver diseases and approximately 25%-40% of HF cases may ultimately progress to hepatic cirrhosis. Hepatic stellate cells (HSCs) contribute significantly to the occurrence of HF and the activation of HSC is the key issue in the pathogenesis of HF. Taurine is a kind of important anti-injury substance in the body.

21 Apr 2010

Inovio Biomedical wins Vaccine Industry Excellence Award in “Best Early Stage Biotech” category

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that the company was awarded a Vaccine Industry Excellence Award in the category of "Best Early Stage Biotech" by a panel of judges composed of a broad selection of biotech industry stakeholders. The award was presented at the World Vaccine Congress being held April 19 - 22, 2010, in Washington, D.C.

21 Apr 2010

Alchemia’s HyACT tumour targeting technology enhances killing of cancer stem cells

Alchemia's subsidiary Alchemia Oncology today presented two posters at the American Association of Cancer Research (AACR) 101st Annual Meeting in Washington, DC. The data demonstrates the ability of the Company's HyACT tumour targeting technology to dramatically enhance the killing of cancer stem cells. These cells are highly resistant to treatment with chemotherapeutic drugs and are believed to be responsible for treatment failure and disease recurrence.

21 Apr 2010

Touch Bionics wins Queen's Awards for Enterprise in Innovation category for 2010

Touch Bionics, developer of advanced upper-limb bionic technologies, today announced it is a winner of the prestigious Queen's Awards for Enterprise with an award in the Innovation category for 2010. The Queen's Awards for Enterprise are the UK's most prestigious awards for business performance.

21 Apr 2010

Posit Science challenges BBC study on cognitive training programs

Posit Science, the leader in clinically proven brain fitness programs, contests the interpretation and methodology used in a British Broadcasting Corporation-sponsored study published in the journal Nature.

21 Apr 2010

MicroRNAs control levels of Myc protein in Drosophila: Researchers

In all cancers, whether in kidney, breast, lung, colon, skin or any other tissue, cells show high Myc protein levels. Excess Myc causes cells to multiply in an exaggerated manner, giving rise to the development of tumours. One of the most pressing questions about Myc is how healthy cells keep the expression of this protein in check.

21 Apr 2010

Ajinomoto AminoScience introduces new resource for peptides

Ajinomoto AminoScience, LLC announced today the launch of AjiPhase™, an evolution of liquid phase peptide synthesis containing the benefits of solid and liquid phase methodologies. This new service is designed as an innovative tool that will enable pharmaceutical companies to expand their development pipeline and provide a uniform production process through the entire development lifecycle.

21 Apr 2010

Immunomedics' blood assay for PAM4-protein can detect pancreatic cancer and predict early relapse

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that a new blood test using the Company's proprietary humanized antibody, clivatuzumab or PAM4, predicted a partial response in an initial set of patients treated with a combination of the antibody labeled with yttrium-90 (Y-90) and gemcitabine. Results were presented at the 101st Annual Meeting of the American Association for Cancer Research.

21 Apr 2010

ARIAD presents AP26113 investigational ALK inhibitor preclinical study data at AACR annual meeting

ARIAD Pharmaceuticals, Inc. today announced results of preclinical studies on its investigational anaplastic lymphoma kinase (ALK) inhibitor - AP26113 - showing potent inhibition of the target protein and of mutant forms that are resistant to the first-generation ALK inhibitor, which currently is in clinical trials in patients with cancer. ARIAD scientists presented these data today at the annual meeting of the American Association for Cancer Research (AACR) in Washington, D.C.

21 Apr 2010

Medical Science News

University of Nevada professor awarded NIH RO1 grant for study of control of motility in internal anal sphincter

Agios Pharmaceuticals presents data on cancer-associated IDH1 mutations at 101st AACR meeting

SpectraCell Laboratories introduces apolipoprotein E genotyping

Study links mutations in RAD51C gene to breast and ovarian cancer

No more needles for vaccines – a two minute Nanopatch may suffice, say researchers

Affymetrix reports first-quarter total revenue of $80.2M

Red wine consumption may protect brain from stroke damage, say Johns Hopkins researchers

Curis presents data on CU-906 compound designed to inhibit HDAC and PI3K/mTOR targets simultaneously

BIO-key International, Healthcare-ID to present biometric identity solutions at 56th CBBS Annual Meeting

CDI's iCell Cardiomyocytes named to MIT Technology Review's Annual 10 Emerging Technologies List

NCGR deploys Isilon scale-out NAS to power genome sequencing research services

Study helps understand molecular mechanism underlying taurine's protection against hepatic fibrosis

Inovio Biomedical wins Vaccine Industry Excellence Award in “Best Early Stage Biotech” category

Alchemia’s HyACT tumour targeting technology enhances killing of cancer stem cells

Touch Bionics wins Queen's Awards for Enterprise in Innovation category for 2010

Posit Science challenges BBC study on cognitive training programs

MicroRNAs control levels of Myc protein in Drosophila: Researchers

Ajinomoto AminoScience introduces new resource for peptides

Immunomedics' blood assay for PAM4-protein can detect pancreatic cancer and predict early relapse

ARIAD presents AP26113 investigational ALK inhibitor preclinical study data at AACR annual meeting

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News